All In Biotech

Drug Trial Radar · NCT01749878

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Last checked: Nov 20, 2026Latest source record: May 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

99

Actual

Start

Dec 2012

Primary completion

Jan 2016

Study completion Jan 2016

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Dec 17, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 1, first-in-human, randomized, ascending single-dose, placebo-controlled, double-blind study of the safety, tolerability, and bioeffect of REGN1500

Conditions

  • Hypertriglyceridemia

Interventions

  • REGN1500Drug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: Day 1 to Day 106/126

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.